Procept Biorobotics Ownership
| PRCT Stock | USD 95.59 1.70 1.75% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Procept |
Procept Stock Ownership Analysis
About 86.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.95. Procept Biorobotics Corp had not issued any dividends in recent years. PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California. Procept Biorobotics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 234 people. To find out more about Procept Biorobotics Corp contact Reza Zadno at 650 232 7200 or learn more at https://www.procept-biorobotics.com.Besides selling stocks to institutional investors, Procept Biorobotics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Procept Biorobotics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Procept Biorobotics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Procept Biorobotics Quarterly Liabilities And Stockholders Equity |
|
Procept Biorobotics Insider Trades History
About 5.0% of Procept Biorobotics Corp are currently held by insiders. Unlike Procept Biorobotics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Procept Biorobotics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Procept Biorobotics' insider trades
Procept Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Procept Biorobotics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Procept Biorobotics Corp backward and forwards among themselves. Procept Biorobotics' institutional investor refers to the entity that pools money to purchase Procept Biorobotics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cpmg Inc | 2024-06-30 | 958.3 K | Westfield Capital Management Company, Lp | 2024-09-30 | 905.7 K | Jpmorgan Chase & Co | 2024-06-30 | 896.7 K | Franklin Resources Inc | 2024-09-30 | 886 K | Summit Partners Public Asset Management, Llc | 2024-06-30 | 762.7 K | Lord, Abbett & Co Llc | 2024-09-30 | 748.6 K | Mirae Asset Global Etfs Holdings Ltd. | 2024-06-30 | 683.7 K | Champlain Investment Partners, Llc | 2024-09-30 | 650.3 K | Bank Of America Corp | 2024-06-30 | 647.2 K | Fmr Inc | 2024-09-30 | 7.3 M | Vanguard Group Inc | 2024-09-30 | 4.8 M |
Procept Biorobotics Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Procept Biorobotics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Procept Biorobotics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Procept Biorobotics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Procept Biorobotics Outstanding Bonds
Procept Biorobotics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Procept Biorobotics Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Procept bonds can be classified according to their maturity, which is the date when Procept Biorobotics Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PROCTER GAMBLE 645 Corp BondUS742718BH18 | View | |
| US742718AV11 Corp BondUS742718AV11 | View | |
| PROCTER GAMBLE 55 Corp BondUS742718CB39 | View | |
| PROCTER GAMBLE 555 Corp BondUS742718DF34 | View | |
| PROCTER GAMBLE 58 Corp BondUS742718DB20 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| PROCTER GAMBLE 245 Corp BondUS742718ER62 | View | |
| PROCTER GAMBLE 27 Corp BondUS742718EP07 | View |
Procept Biorobotics Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 30th of October 2024 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Procept Stock Analysis
When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.